Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 22, 2021
Ad hoc announcement pursuant to Art. 53 LR Sanifit Therapeutics and Inositec AG, both clinical stage biopharmaceutical companies, are developing first-in-class treatments for progressive vascular...
-
Nov 12, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of first orally administered therapy for the treatment of ANCA-associated...
-
Oct 27, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Phase-III trial did not demonstrate a statistically significant difference from placebo on the primary endpoint of estimated Glomerular Filtration Rate...
-
Oct 12, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing St. Gallen, Switzerland,...
-
Sep 27, 2021
First orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan Partner Kissei to market TAVNEOS® in Japan, with launch expected as soon as...